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Abstract Protein kinase D (PKD) is a serine/threonine kinase
that binds phorbol esters in a phospholipid-dependent manner via
a tandemly repeated cysteine-rich, zinc finger-like motif (the
cysteine-rich domain, CRD). Here, we examined whether the
individual cysteine-rich motifs of the CRD of PKD (referred to
as cys1 and cys2) are functionally equivalent in mediating
phorbol ester binding both in vivo and in vitro. Our results
demonstrate that the cys1 and cys2 motifs of the CRD of PKD
are functionally dissimilar, with the cys2 motif responsible for the
majority of [3H]phorbol 12,13-dibutyrate (PDB) binding, both in
vivo and in vitro.
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1. Introduction
Protein kinase C (PKC), a major target for the tumor pro-
moting phorbol esters, plays a critical role in signal transduc-
tion through its activation by the second messenger diacyl-
glycerol (DAG) [1,2]. The NH2-terminal regulatory region
of classical (K, L, Q) and novel (N, O, R, a) members of the
PKC family contains a tandem repeat of conserved cysteine-
rich, zinc ¢nger-like motifs [3^5] that mediates phospholipid-
dependent DAG/phorbol ester binding [6^12]. An emerging
theme in the elucidation of the role of this domain is that
the individual cysteine-rich motifs appear to play non-equiv-
alent functions in mediating phorbol ester binding and trans-
location [9,13^15].
The newly identi¢ed protein kinase D (PKD) is a mouse
serine/threonine protein kinase with distinct structural and
enzymological properties [16]. The catalytic domain of PKD
is distantly related to Ca2-regulated kinases and shows little
similarity to the highly conserved regions of the kinase sub-
domains of the PKC family [17]. Consistent with this, PKD
does not phosphorylate a variety of substrates utilized by
PKCs, indicating that PKD is a protein kinase with distinct
substrate speci¢city [16,18]. However, the amino-terminal
region of PKD contains a tandem repeat of cysteine-rich, zinc
¢nger-like motifs (cys1 and cys2) that binds phorbol esters
with high a⁄nity [16]. Immunopuri¢ed PKD is markedly
stimulated by either biologically active phorbol esters or
DAG, in the presence of phosphatidylserine (PS) [18,19].
The human protein kinase PKCW [20] with 92% homology
to PKD is also stimulated by phorbol esters and phospho-
lipids [21]. These in vitro results indicate that PKD/PKCW is
a novel phorbol ester/DAG-stimulated kinase.
Interestingly, there are a number of important di¡erences
between the cysteine-rich domain (CRD) of PKCs and PKD.
The length of the amino-acid sequence separating the individ-
ual cysteine-rich motifs of PKD (95 residues) is substantially
longer than that of classical PKCs (28 residues) or novel
PKCs (35^36 residues) and the residues leucine-147, alanine-
154, alanine-156, methionine-164 and tyrosine-182 in cys1 and
residues lysine-298 and cysteine-314 in cys2 di¡er from the
PKC cysteine-rich consensus motif [16]. In contrast to all
known PKCs including mammalian, Drosophila and yeasts
isoforms [22], the NH2-terminal region of PKD contains a
putative transmembrane sequence and a pleckstrin homology
(PH) domain interposed between cys2 and the catalytic do-
main that regulates enzyme activity [23]. Furthermore, PKD
does not possess a sequence with homology to a typical PKC
autoinhibitory pseudosubstrate motif located upstream of the
CRD [16,24]. The striking di¡erences between PKD and
PKCs as well as between cys1 and cys2, prompted us to ex-
amine whether these cysteine-rich motifs of the PKD CRD
play equivalent roles in mediating phorbol ester binding to
PKD.
The results presented here demonstrate that the cys1 and
cys2 motifs of the CRD of PKD are functionally dissimilar,
with the cys2 motif responsible for the majority of [3H]PDB
binding, both in vivo and in vitro.
2. Materials and methods
2.1. Deletion mutants and site-directed mutagenesis
Deletion mutants were generated by direct-rapid mutagenesis of
large plasmids using PCR with rTth DNA polymerase XL with
proof-reading capability (Gene Amp XL PCR Kit, Perkin-Elmer).
Deletion of the entire CRD domain, amino acids H145^D353
(vCRD), deletion of the cys1 motif, amino acids H145^S223 (vcys1)
and deletion of the cys2 motif, amino acids H277^D353 (vcys2) were
made directly in PKD-cDNA cloned in pBluescript-SK(+) using oli-
gonucleotide primers starting upstream (reverse primer, Rp) and
downstream (forward primer, Fp) from the desired deletion and con-
tained the unique restriction site AscI (see Table 1). PCR was per-
formed using a DNA Thermal Cycler (Perkin-Elmer) applying a short
number of cycles (9 cycles) starting with a large amount of template
DNA (1 Wg). The PCR parameters were optimized for the oligonu-
cleotides used. After PCR, template DNA was eliminated by DpnI
digestion. Ampli¢ed DNA was cut with AscI and religated. The re-
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sulting deletion construct was then subcloned into the mammalian
expression vector pcDNA3 for transient expression in COS-7 cells.
Site-speci¢c mutations within the CRD domain of PKD resulting in
single amino acid substitutions (P155G and P287G) were generated by
overlap PCR using pBluescript SK(+)-PKD cDNA (pBS-PKD). A
sequence upstream of PKD cDNA corresponding to pBSK and close
to the polylinker and a sequence near to the SphI site (at nucleotide
1758) within PKD cDNA were used as external forward and reverse
primers together with internal reverse and forward primers, respec-
tively, containing the residue substitutions P155(CCA) to G155(GGA)
and/or P287(CCC) to G287(GGC) (see Table 1). After the second
PCR reaction the ampli¢ed fragment was digested with XhoI and
SphI. pBSK-PKD was also digested with these two restriction en-
zymes and the wild-type PKD-XhoI/SphI fragment was then replaced
by the PCR product containing the desired mutation(s). Constructs
were subcloned into the mammalian expression vector pcDNA3 for
transient expression in COS-7 cells. All constructs were analyzed by
DNA restriction enzyme analysis and sequencing and were shown to
contain the desired deletion or mutations.
2.2. Glutathione S-transferase (GST)-fusion protein expression and
puri¢cation
The sequences spanning the entire CRD domain of PKD (residues
105^353) were ampli¢ed by PCR from either wild-type (GST-CRD
WT) or mutant (GST-CRD P155G; GST-CRD P287G; GST-CRD
P155/287G) cDNA sequences using the speci¢c oligonucleotide
primers 5P-GCCGGATCCGATCCTGCCTCCGACAAC and 3P-
GCGGAATTCCATCACTCCCTTCTTCCAT. PCR products were
then subcloned into the pGEX4T3 vector (Pharmacia) using the Bam-
HI and EcoRI restriction sites underlined. All constructs were checked
by sequencing. Expression of GST-fusion proteins in E. coli was in-
duced by the addition of isopropyl-L-D-thiogalactopyranoside at a
¢nal concentration of 0.4 mM for 3 h at 37‡C. Bacteria were har-
vested by centrifugation and lysed in 10 ml lysis bu¡er containing 1%
Triton X-100, 2 mM EDTA, 1 mM phenylmethylsulfonyl £uoride, 10
Wg/ml leupeptin, 10 Wg/ml aprotinin in phosphate bu¡ered saline
(PBS). Lysates were sonicated on ice, clari¢ed by centrifugation and
GST-fusion proteins were puri¢ed by incubation with glutathione
agarose beads for 2 h at 4‡C. The beads were then washed and
GST-fusion proteins were eluted with 25 mM reduced glutathione.
The eluted fractions were dialyzed against PBS before they were
stored at 320‡C.
2.3. Cell culture and transient transfection
COS-7 cells were plated in 60-mm dishes at 3U105 cells/dish in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 10% fetal
bovine serum and used for transfection 1 day later. Exponentially
growing COS-7 cells, 40^60% con£uent, were transfected with PKD
mammalian expression plasmids using Lipofectin (Life Technologies)
as previously described [23,25].
2.4. [3H]Phorbol 12,13-dibutyrate (PDB) binding assays
[3H]PDB binding to intact COS-7 cells was performed as described
previously [26]. Brie£y, cultures were washed twice with DMEM and
incubated with binding medium (DMEM containing 1 mg/ml bovine
serum albumin) and 10 nM [3H]PDB at 37‡C for 30 min. The cultures
were then rapidly washed at 4‡C with PBS containing 1 mg/ml bovine
serum albumin and lysed with NaOH-SDS. Bound radioactivity was
determined by liquid scintillation counting. Non-speci¢c binding was
determined in the presence of 10 WM unlabeled PDB.
In vitro binding of [3H]PDB to GST-fusion proteins was analyzed
by incubating 100 ng of GST-fusion proteins with various concentra-
tions of [3H]PDB and 125 Wg/ml PS in the presence of 20 mM Tris-
HCl (pH 7.5) in a ¢nal volume of 200 Wl for 60 min at 4‡C. Fusion
proteins were recovered by the addition of 300 Wl of DE52 cellulose
equilibrated with 20 mM Tris-HCl, pH 7.5 (50:50 suspension) for 20
min at 4‡C. Incubations were terminated by rapid ¢ltration on a
Whatman GF/F glass ¢lter disc followed by rapid washing with 20
mM Tris-HCl, pH 7.5, at 4‡C. Bound radioactivity was determined by
liquid scintillation counting. Non-speci¢c binding was determined by
the addition of 10 WM unlabeled PDB to the incubation mixture. PS
was sonicated for 1 min at 4‡C to form phospholipid micelles.
2.5. Western blot analysis
COS-7 cells were washed twice in ice-cold PBS and lysed in 50 mM
Tris-HCl, pH 7.5, 2 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol,
10 Wg/ml aprotinin, 10 Wg/ml leupeptin, 1 mM 4-(2P-aminoethyl)-ben-
zenesulfonyl £uoride hydrochloride and 1% Triton X-100 (bu¡er A).
For Western blotting of wild-type and mutant PKD expression levels,
50 Wg of protein from lysates were extracted for 10 min at 95‡C in 2U
SDS-PAGE sample bu¡er and analyzed by polyacrylamide gel elec-
trophoresis (SDS-PAGE) followed by transfer to Immobilon mem-
branes at 100 V, 0.4 A at 4‡C for 4 h using a Bio-Rad transfer
apparatus. The composition of the transfer bu¡er was 200 mM glyc-
ine, 25 mM Tris, 0.01% SDS and 20% CH3OH. Membranes were
blocked using 5% non-fat dried milk in PBS, pH 7.2 and incubated
with PA-1 antiserum (1:500) at room temperature for 3 h in PBS
containing 3% non-fat dried milk. Immunoreactive bands were visual-
ized using 125I-protein A and autoradiography.
2.6. Materials
[3H]PDB (0.25 mCi/ml) and 125I-protein A (15 mCi/ml) were from
Amersham International (UK). PDB was obtained from Sigma. Pro-
tein A agarose was from Boehringer Mannheim. Oligonucleotide pri-
mers were synthesized at the Imperial Cancer Research Fund. All
other items were from standard suppliers or as indicated in the text.
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Table 1
Oligonucleotides used for mutagenesis
Mutant Position Oligonucleotide Sequence
Deletion mutant vCys1 Fp: 795^820 5P-GTC AGG CGC GCC GTC CCT GAT GAG CCT TTA CTG TCT C-3P
Rp: 540^557 5P-GTC AGG CGC GCC AGG GCC GGA TCT GGA AGT C-3P
vCys2 Fp: 1185^1207 5P-GTC AGG CGC GCC AAT GAC AGT GAG CGG AAC AGT GG-3P
Rp: 931^952 5P-GTC AGG CGC GCC AAG GCA CCT TCA CCT TAG ACA TCA-3P
vCRD Fp: 1185^1207 5P-GTC AGG CGC GCC AAT GAC AGT GAG CGG AAC AGT GG-3P
Rp: 540^557 5P-GTC AGG CGC GCC AGG GCC GGA TCT GGA AGT C-3P
Single amino acid substitutions P155G External Fp: pB-SK(+) 5P-GAC TCA CTA TAG GGC GAA TTG GGT ACC G-3P
Internal Rp: 577^598 5P-CA GAA AGC TCC GGC TC TGT ATG-3P
Internal Fp: 577^598 5P-CA TAC AGA GCC GGA GCT TTC TG-3P
External Rp: 1758^1781 5P-CTT GGG GAT GAC GGG CAT AAG AGC-3P
P287G External Fp: pB-SK(+) 5P-GAC TCA CTA TAG GGC GAA TTG GGT ACC G-3P
Internal Rp: 974^995 5P-GCA GAC CGT GCC CCG TGT GTA G-3P
Internal Fp: 974^995 5P-C TAC ACA CGG GGC ACG GTC TGC-3P
External Rp: 1758^1781 5P-CTT GGG GAT GAC GGG CAT AAG AGC-3P
Position and sequence of the oligonucleotides annealing to PKD cDNA for the construction of di¡erent mutants: Fp (forward primer) and Rp
(reverse primer). Nucleotides of AscI restriction site are underlined. Speci¢c nucleotides changed for single amino acid substitutions are in bold.
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3. Results and discussion
3.1. Speci¢c [3H]PDB binding to COS-7 cells transfected with
wild-type PKD or PKD with deletions of cys1, cys2 or the
entire CRD
To determine the contribution of the individual cysteine-
rich motifs to high a⁄nity phorbol ester binding by PKD in
vivo, we deleted the ¢rst (vcys1) or the second (vcys2) cys-
teine-rich motif as well as the entire CRD (vCRD) of PKD
(Fig. 1A). The cDNAs encoding wild-type and the mutant
PKDs were subcloned into the mammalian expression vector
pcDNA3 and transiently transfected into COS-7 cells. As il-
lustrated in Fig. 1B, speci¢c binding of 10 nM [3H]PDB to
COS-7 cells expressing wild-type PKD showed a 12-fold in-
crease over vector control levels. COS-7 cells expressing a
PKD mutant lacking the cys1 motif (vcys1) retained a signi¢-
cant degree of speci¢c [3H]PDB binding (V50% as compared
to wild-type PKD). In striking contrast, COS-7 cells express-
ing a PKD mutant lacking cys2 (vcys2) did not exhibit any
signi¢cant increase in speci¢c [3H]PDB over control
(pcDNA3) levels. In fact, a deletion of the cys2 motif was
as e¡ective as a deletion of the entire CRD (vCRD) in elim-
inating speci¢c [3H]PDB binding to PKD in vivo (Fig. 1B).
All PKD constructs (PKD, vcys1, vcys2 and vCRD) exhib-
ited similar levels of expression, as shown by Western blotting
with a speci¢c antibody directed against the C-terminal region
of PKD (Fig. 1B, lower panel).
3.2. Speci¢c 3[H]PDB binding to COS-7 cells transfected with
wild-type PKD or PKD with single amino-acid
substitutions within cys1, cys2 or both
The results presented in Fig. 1 suggested that the cys1 and
cys2 motifs of PKD have dissimilar [3H]PDB binding proper-
ties. Alternatively, these results could arise from conforma-
tional changes introduced into the structure of PKD by these
deletions. Consequently, we examined the in vivo binding of
[3H]PDB to COS-7 cells expressing wild-type and mutant
forms of PKD containing single amino acid substitutions in
cys1, cys2 or in both cysteine-rich motifs. Since a highly con-
served proline residue present in the cysteine-rich motifs of all
DAG/phorbol ester sensitive proteins has previously been
shown to be critical for high a⁄nity phorbol ester binding
[11], we generated PKD mutants which contained single ami-
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Fig. 2. Binding of [3H]PDB to COS-7 cells expressing wild-type and
point mutants of PKD. A: Schematic representation of the PKD
expression constructs containing single (P155G, P287G) or double
(P155/287G) amino-acid substitutions in the cys1 and cys2 motifs of
the PKD CRD. B, upper panel: Binding of [3H]PDB to PKD wild-
type or mutant PKDs with single amino acid substitutions expressed
in COS-7 cells. Total (¢lled columns) and non-speci¢c binding (open
columns) of 10 nM [3H]PDB to COS-7 cells expressing vector con-
trol (pcDNA3), wild-type PKD (PKD) or PKD CRD mutants
(P155G, P287G and P155/287G) are shown, expressed as cpm
U1033/106 cells. Non-speci¢c binding was measured in the presence
of 10 WM unlabeled PDB. Values shown are the mean þ S.E. from
three individual experiments. Lower panel: Western blot showing
the expression of the di¡erent PKD CRD mutants in transfected
cells. Fifty Wg of total protein from lysates were separated by SDS-
PAGE and immunoblotted with the PA-1 antiserum as speci¢ed in
Section 2.
Fig. 1. Binding of [3H]PDB to COS-7 cells expressing wild-type and
deletion mutants of PKD. A: Schematic representation of the PKD
expression constructs containing deletions of either the cys1 (vcys1)
or cys2 (vcys2) motifs or of the entire CRD (vCRD). B: Upper
panel: Binding of [3H]PDB to PKD CRD domain deletion mutants
expressed in COS-7 cells. Total (¢lled columns) and non-speci¢c
binding (open columns) of 10 nM [3H]PDB to COS-7 cells express-
ing vector control (pcDNA3), wild-type (PKD) or deletion mutants
(vcys1, vcys2 and vCRD) of PKD are shown, expressed as cpm
U1033/106 cells. Non-speci¢c binding was measured in the presence
of 10 WM unlabeled PDB. Values shown are the mean þ S.E. from
three independent experiments. Lower panel: Western blot showing
the expression of the di¡erent PKD CRD deletion mutants in trans-
fected cells. Fifty Wg of total protein from the cell lysates were sepa-
rated by SDS-PAGE and immunoblotted with the PA-1 antiserum
as speci¢ed in Section 2.
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no-acid substitutions at this site in the ¢rst (P155G), second
(P287G) or in both (P155/287G) cysteine-rich motifs of PKD
(Fig. 2A).
The level of speci¢c binding of 10 nM [3H]PDB to COS-7
cells expressing a PKD mutant with a proline to glycine mu-
tation in cys1 (P155G) was comparable to that seen in COS-7
cells expressing wild-type PKD (Fig. 2B). In striking contrast,
speci¢c [3H]PDB binding to COS-7 cells expressing the P287G
or the P155/287G mutants of PKD was not signi¢cantly in-
creased over COS-7 cells expressing vector alone, despite sim-
ilar levels of expression of all these constructs (Fig. 2B). To-
gether, these results indicate that the majority of speci¢c
[3H]PDB binding to PKD in vivo is mediated through the
cys2 motif.
3.3. Speci¢c [3H]PDB binding to wild-type and mutant
GST-fusion proteins comprising the entire CRD of PKD
We subsequently used a di¡erent approach to corroborate
the non-equivalent roles of cys1 and cys2 of PKD in phorbol
ester binding. We produced GST-fusion proteins of the CRD
domain of PKD, either wild-type or containing single or dou-
ble mutations at the conserved proline residues within the cys1
and cys2 motifs described above. The GST-fusion protein
preparations used in this study migrated on SDS-PAGE gels
at the predicted MW (Fig. 3A). The speci¢c binding of in-
creasing concentrations of [3H]PDB (2^200 nM) to a GST-
fusion protein of the wild-type PKD CRD (GST-CRD WT) is
shown in Fig. 3B. Scatchard analysis of this binding curve
showed two classes of binding sites (Fig. 3B, inset), a pattern
observed in four independent experiments (Kd values of 3 and
49 nM, respectively). In view of the results presented in Figs. 1
and 2, the biphasic Scatchard plot could be the consequence
of dissimilar a⁄nities of cys1 and cys2 for [3H]PDB in the
context of the PKD CRD, e.g. cys2 mediates high a⁄nity
binding whereas cys1 provides the low a⁄nity site. In agree-
ment with this hypothesis, a fusion protein of the CRD con-
taining a proline to glycine mutation within the cys2 motif
(GST-CRD P287G) had a greatly reduced [3H]PDB binding
a⁄nity (Kd = 55 þ 8 nM; Fig. 3C). In contrast, a GST-fusion
protein of the PKD CRD containing the comparable proline
to glycine mutation within the cys1 motif (GST-CRD P155G)
retained the high a⁄nity component for [3H]PDB binding
(Kd = 10 þ 2 nM; Fig. 3C). No signi¢cant [3H]PDB binding
to the double mutant (GST-CRD P155G/287G) could be de-
tected using a range of fusion protein amounts (0.2^2 Wg) or
[3H]PDB concentrations (2^200 nM; data not shown). GST
alone did not bind [3H]PDB.
3.4. Conclusions
Our results demonstrate that the cys1 and cys2 motifs of the
PKD CRD di¡er in their ability to mediate speci¢c phorbol
ester binding to this kinase. Mutational analysis of the CRD
of PKD followed by in vivo and in vitro binding studies in-
dicate that the major site for phorbol ester binding to PKD
lies within the cys2 motif. We conclude that the cys1 and cys2
motifs play distinct roles in the regulation of PKD.
It is increasingly recognized that the individual cysteine-rich
motifs of classical and novel PKCs play non-equivalent func-
tions in mediating phorbol ester binding to these enzymes
[9,13^15]. Our ¢ndings with PKD, which contains a CRD
that di¡ers from those of classical and novel PKCs (see Sec-
tion 1 for details), suggests that this functional non-equiva-
lence of cysteine-rich motifs may be a conserved feature of
DAG/phorbol ester sensitive proteins that contain a tandem
repeat of these motifs.
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Fig. 3. In vitro binding of [3H]PDB to GST-fusion proteins of the
PKD CRD. A: GST-fusion proteins of wild-type or mutant CRDs
of PKD were generated as described in Section 2. Fusion protein
puri¢cation was analyzed by SDS-PAGE and Coomassie blue stain-
ing. B: In vitro binding of [3H]PDB (2^200 nM) to 100 ng of GST-
CRD WT was carried out as described in Section 2. The results
shown are expressed as speci¢c cpm bound. Non-speci¢c binding
was 6 10% of the total binding. All binding measurements were
carried out in duplicate. Inset: Scatchard analysis (bound/free vs.
bound) of the binding curve for GST-CRD WT. The Kd values for
[3H]PDB were determined by linear regression analysis. Results
shown are representative of four independent experiments and the
Kd values are the mean þ S.E. of the four experiments. C: Scatchard
analysis of the in vitro [3H]PDB binding curves for GST-CRD
P155G and GST-CRD P287G. Results shown (bound/free vs.
bound) were determined as for panel B and are representative of
three independent experiments. The Kd values of [3H]PDB binding
to these mutant CRD fusion proteins were calculated by linear re-
gression analysis and the results shown are the mean þ S.E. of three
experiments.
T. Iglesias et al./FEBS Letters 437 (1998) 19^2322
References
[1] Nishizuka, Y. (1995) FASEB J. 9, 484^496.
[2] Exton, J.H. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 481^509.
[3] Dekker, L.V., Palmer, R.H. and Parker, P.J. (1995) Curr. Opin.
Struct. Biol. 5, 396^402.
[4] Newton, A.C. (1995) J. Biol. Chem. 270, 28495^28498.
[5] Hurley, J.H., Newton, A.C., Parker, P.J., Blumberg, P.M. and
Nishizuka, Y. (1997) Protein Sci. 6, 477^480.
[6] Ono, Y., Fujii, T., Igarashi, K., Kuno, T., Tanaka, C., Kikkawa,
U. and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. USA 86,
4868^4871.
[7] Burns, D.J. and Bell, R.M. (1991) J. Biol. Chem. 266, 18330^
18338.
[8] Hubbard, S.R., Bishop, W.R., Kirschmeier, P., George, S.J.,
Cramer, S.P. and Hendrickson, W.A. (1991) Science 254, 1776^
1779.
[9] Quest, A.F. and Bell, R.M. (1994) J. Biol. Chem. 269, 20000^
20012.
[10] Quest, A.F., Bardes, E.S. and Bell, R.M. (1994) J. Biol. Chem.
269, 2961^2970.
[11] Kazanietz, M.G., Wang, S., Milne, G.W., Lewin, N.E., Liu, H.L.
and Blumberg, P.M. (1995) J. Biol. Chem. 270, 21852^21859.
[12] Zhang, G., Kazanietz, M.G., Blumberg, P.M. and Hurley, J.H.
(1995) Cell 81, 917^924.
[13] Shieh, H.L., Hansen, H., Zhu, J. and Riedel, H. (1995) Mol.
Carcinogen. 12, 166^176.
[14] Slater, S.J., Ho, C., Kelly, M.B., Larkin, J.D., Taddeo, F.J.,
Yeager, M.D. and Stubbs, C.D. (1996) J. Biol. Chem. 271,
4627^4631.
[15] Szallasi, Z., Bogi, K., Gohari, S., Biro, T., Acs, P. and Blumberg,
P.M. (1996) J. Biol. Chem. 271, 18299^18301.
[16] Valverde, A.M., Sinnett-Smith, J., Van Lint, J. and Rozengurt,
E. (1994) Proc. Natl. Acad. Sci. USA 91, 8572^8576.
[17] Rozengurt, E., Sinnett-Smith, J., Van Lint, J. and Valverde,
A.M. (1995) Mutat. Res. 333, 153^160.
[18] Van Lint, J.V., Sinnett-Smith, J. and Rozengurt, E. (1995) J. Biol.
Chem. 270, 1455^1461.
[19] Zugaza, J.L., Sinnett-Smith, J., Van Lint, J. and Rozengurt, E.
(1996) EMBO J. 15, 6220^6230.
[20] Johannes, F.J., Prestle, J., Eis, S., Oberhagemann, P. and P¢zen-
maier, K. (1994) J. Biol. Chem. 269, 6140^6148.
[21] Dieterich, S., Herget, T., Link, G., Boºttinger, H., P¢zenmaier, K.
and Johannes, F.J. (1996) FEBS Lett. 381, 183^187.
[22] Toda, T., Shimanuki, M. and Yanagida, M. (1993) EMBO J. 12,
1987^1995.
[23] Iglesias, T. and Rozengurt, E. (1998) J. Biol. Chem. 273, 410^
416.
[24] Rozengurt, E., Sinnett-Smith, J. and Zugaza, J.L. (1997) Bio-
chem. Soc. Trans. 25, 565^571.
[25] Matthews, S.A., Pettit, G.R. and Rozengurt, E. (1997) J. Biol.
Chem. 272, 20245^20250.
[26] Collins, M.K. and Rozengurt, E. (1984) J. Cell. Physiol. 118,
133^142.
FEBS 20948 19-10-98
T. Iglesias et al./FEBS Letters 437 (1998) 19^23 23
